Valeant Pharmaceuticals International Inc (VRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Transcription

1 Valeant Pharmaceuticals International Inc (VRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

2 Valeant Pharmaceuticals International Inc (VRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile The Business Research Store is run by Sector Publishing Intelligence Ltd. SPi has been selling professional market research reports and company analyses for over 7 years. Our experienced staff team are on hand to help with any research enquiries you may have, and help you find the right report for your needs. We sell reports to businesses of all sizes across the world who need current market data to plan and develop their business strategies. We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document. We look forward to being of service to you. If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf. Phone: +44 (0) or office@sectorpublishing.com 2

3 Valeant Pharmaceuticals International Inc (VRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Summary Valeant Pharmaceuticals International Inc (Valeant) develops, manufactures and markets several branded, overthe-counter (OTC) and generic drugs. The company also offers medical devices such as medical contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. Valeant offers products in the areas of dermatology, neurology, eye health and branded generics. It offers a diverse mix of products in various regions across the world including the US, Canada, Australasia, Latin America, and Central and Eastern Europe. The company has manufacturing facilities in Canada, Mexico, the US and countries in Europe, North Africa, Asia and South America. Valeant is headquartered in Laval, Quebec, Canada. Valeant Pharmaceuticals International Inc (VRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Pharma etrack deals database, and primary and secondary research. Scope - Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company's operations. - Key Employees - A list of the key executives of the company. 3

4 - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements - The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy - The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company s operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Additional Details Publisher : Global Data Reference : GDPH3707D Number of Pages : 206 Report Format : PDF Publisher Information : 4

5 5

6 Table Of Contents for Valeant Pharmaceuticals International Inc (VRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Updated: ] Table of Contents Table of Contents 3List of Tables 7List of Figures 9Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD Valeant Pharmaceuticals International Inc, Medical Devices Deals, 2012 to YTD Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deal Details 24Asset Purchase 24Valeant Canada Acquires Canadian Rights from Sanofi-aventis for Altace and Altace HCT 24Valeant Pharma Acquires Certain Assets of Dendreon for USD495 Million 25Valeant Pharma Acquires Non-Strategic Products from Marathon Pharma 27PharmaSwiss Acquires Trademarks and Intellectual Property of Certain Products from Bristol-Myers Squibb for USD61 Million 28Valeant Canada Acquires Dermatology Products from Valeo Pharma for USD23 Million 29Valeant Pharma Acquires Pharma Brands from Probiotec 30Salix Pharma Acquires Worldwide IP Rights To Amorphous Rifaximin From Olon 32Valeant Pharma Acquires Medical Devices And Food Supplements Assets Of Croma-Pharma 33Valeant Pharma Acquires US Rights To Targretin From Eisai 34Valeant Pharma Acquires Visudyne Business From QLT For Up To USD132.5 Million 35Valeant Pharma Completes Acquisition Of Certain Assets From Swiss Herbal Remedies For US$21 Million 36Valeant Pharma Completes Acquisition Of AcneFree And Certain Assets From University Medical For Up To US$105 Million 37Valeant Pharma Completes Acquisition Of Certain Assets From Atlantis Pharma For Up To US$74 Million 38PreCision Dermatology Acquires Dermatology Products From Triax Pharma 39Valeant Pharma Completes Acquisition Of Branded Generic Products Portfolio From Gerot Lannach For Up To US$184 Million 40Venture Financing 41Precision Dermatology Raises Additional US$26 Million In Venture Financing 41Private Equity 42Pacific Equity and Carlyle Acquires inova Pharma from Valeant Pharma for USD930 Million 42Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 44Partnerships 45Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 45Namtall Enters into Licensing Agreement with Valeant Pharma 47Salix Pharma Enters Into Licensing Agreement With Alfa Wassermann For Rifaximin 48US WorldMeds and Salix Pharma Enter into Co-Promotion Agreement 49Egalet Enters into Co-Promotion Agreement with OraPharma for SPRIX Nasal Spray 50Obagi Medical Products Enters into Distribution Agreement with Nextcell Medical 51Orexigen Therapeutics Enters into Distribution Agreement with Valeant Pharma 52Orexigen Therapeutics Enters Into Distribution Agreement With Valeant For Contrave 53Orexigen Therapeutics Enters into Distribution Agreement with Valeant Pharma for Mysimba 54Swedish Orphan Biovitrum Enters into Distribution Agreement with PharmaSwiss 55Lupin Enters into Distribution Agreement with Salix Pharma 56Synergetics USA Enters Into Agreement With Cleveland Clinic To Develop Next Generation Intraoperative Devices 57Kadmon Pharma Enters Into Co- Promotion Agreement With Valeant Pharma For Syprine Capsules 58Valeant Pharmaceuticals International Partners With Living Proof 59Pharmaxis Enters Into Distribution Agreement With PharmaSwiss For Bronchitol 60Valeant Pharma Enters Into Co-Promotion Agreement With Actavis For Cordran Tape 61Actavis Enters Into Co-Promotion Agreement With Valeant Pharma For Zovirax Cream 62Actavis Enters Into Co-Marketing Agreement With Valeant Pharma For Zovirax Ointment 63Swedish Orphan Biovitrum Enters Into Distribution Agreement With Pharmaswiss 64Valeant Pharma Enters into Option Agreement with Bristol-Myers Squibb 65Gentium Enters Into Distribution Agreement With PharmaSwiss For Defibrotide 66Eisai Europe Enters Into Distribution Agreement With PharmaSwiss For Halaven 67Bausch & Lomb Japan Enters Into Co-Marketing Agreement With Wakamoto Pharma 68Licensing Agreements 69Valeant Pharma Enters into Licensing Agreement with Kaken Pharma for KP Glycyx Pharma to Enter into Licensing Agreement with Valeant Pharma 70Swedish Orphan Biovitrum Enters into Licensing Agreement with Valeant Pharma 71Valeant Pharma Amends Licensing Agreement with AstraZeneca 72Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 73InSite Vision Enters into Licensing Agreement with Nicox for AzaSite, AzaSite Xtr and BromSite 74Cipla Amends Licensing Agreement with Salix Pharma for Rifaximin 75Nicox Exercises Option Agreement with Bausch & Lomb to Co-Promote Latanoprostene Bunod 76Sirona Biochem Expands Licensing Agreement with Valeant Pharma 77Salix Pharma Enters Into Licensing Agreement With RedHill Biopharma For 6

7 RHB-106 Encapsulated Bowel Preparation Product 78Sirona Biochem Enters Into Licensing Agreement With Obagi Medical For TFC Valeant Pharma Enters into Licensing Agreement with SMG Pharma 80Medicis Pharma Enters Into Licensing Agreement With Specialty Pharma Company 81Medicis Pharma Enters Into Licensing Agreement With 3M For Immune Response Modifiers 82Valeant Pharma Enters into Licensing Agreement with Norgine 83Valeant Canada Enters into Licensing Agreement with Takeda Pharma for Edarbi and Edarbyclor 84Bausch & Lomb Enters Into Licensing Agreement With Paragon BioTeck For Phenylephrine 85Bausch & Lomb Enters Into Licensing Agreement With Eye Therapies For Technology To Treat Ocular Redness 86Equity Offering 87Valeant Pharma Plans to Raise Funds through Public Offering of Securities 87Atlantic Healthcare Raises USD24 million in Private Placement of Shares 88Valeant Pharma Raises USD1162 Million in Public Offering of Common Stock 89Valeant Pharma Completes Public Offering Of Shares For US$2.3 Billion 91Bausch & Lomb Withdraws IPO 93Debt Offering 95Valeant Pharma Raises USD586.5 Private Placement of 8.5% Notes Due Valeant Pharma Raises USD1.17 Billion in Private Placement of 9.25% Senior Notes Due Valeant Pharma Raises USD1.18 Billion in Private Placement of 9% Notes Due Valeant Pharma Raises USD591.4 Million in Private Placement of 5.5% Notes Due Valeant Pharma Raises USD801.4 Million in Private Placement of Notes 99Valeant Pharma Raises USD1.5 Billion in Public Offering of 7% Notes Due Valeant Pharma Raises USD1 Billion in Public Offering of 6.5% Notes Due Valeant Pharma Raises USD3.25 Billion in Private Placement of 5.875% Notes Due Valeant Pharma Raises USD1.58 Billion in Private Placement of 4.5% Notes Due Valeant Pharma Raises USD2 Billion in Private Placement of 5.375% Notes Due Valeant Pharma Raises USD3.25 Billion in Private Placement of 6.125% Notes Due Valeant Pharma Raises USD1 Billion in Private Placement of 5.5% Senior Notes Due Valeant Pharma to Raises USD8.8 Billion in Public Offering of Bonds 107Valeant Pharma to Raises USD2.5 Billion in Public Offering of Notes 108Valeant Pharma Completes Private Placement Of Notes Due 2021 For US$900 Million 109Valeant Pharma Completes Private Placement Of Notes Due 2021 For US$1.62 Billion 110Valeant Pharma Completes Private Placement Of Notes Due 2018 For US$1.6 Billion 111Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$1.75 Billion 112Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$500 Million 113Medicis Pharma Completes Public Offering Of Convertible Senior Notes Due 2017 For US$500 Million 114Salix Pharma Completes Private Placement Of 1.5% Convertible Senior Notes Due 2019 For US$690 Million 116Asset Transactions 117Pharming Acquires Rights to Ruconest from Valeant Pharma for USD125 Million 117Valeant Pharma Receives Unsolicited Bids for its Core Assets 119Valeant Pharma May Sell its Dermatology and Cancer Drugs 120Valeant Pharma Plans to Sell Neuro Business 121IGI Labs Acquires Two Ophthalmic Drug Products from Valeant Pharma for USD1.5 Million 122Galderma Completes Acquisition of Aesthetic Dermatology Assets from Valeant Pharma for USD1.4 Billion 123Piramal Enterprises Acquires Caladryl Brand From Valeant Pharma 124Hyperion Therapeutics Completes Acquisition Of Rights To Buphenyl And Ammonul From Ucyclyd Pharma For US$51 Million 125Actavis Acquires Worldwide Rights To Metronidazole 1.3% Vaginal Gel From Valeant Pharma For US$55 Million 127PreCision Dermatology Acquires Dermatology Products From Triax Pharma 128Hyperion Therapeutics Acquires Rights Of Ravicti From Ucyclyd Pharma 129Mylan Acquires Clindamycin Phosphate And Benzoyl Peroxide Gel From Valeant Pharma International 130Acquisition 131Valeant Pharma Sells Sprout Pharma 131Haitong International Zhonghua Finance Acquires Obagi Medical Products from Valeant Pharma for USD190 Million 132Sanpower Acquires Dendreon Pharma from Valeant Pharma for USD820 Million 133Pershing Square Capital Management Sells its Investment in Valeant Pharma 134Takeda Pharma May Acquire Salix Pharma for up to USD10 Billion 135Valeant Pharma May Sell Amoun Pharma 136Valeant Pharma to Acquire Mercury (Cayman) 137Valeant Pharma Acquires Sprout Pharma 139Valeant Pharma Acquires Salix Pharma for USD10.9 Billion 141Valeant Pharma Acquires Nicox for USD20 Million 144Valeant Canada Acquires CROMA Pharma Canada 145Valeant Pharma Completes Acquisition of PreCision Dermatology 146Valeant Pharma Acquires ECR Pharma from Akorn for USD41 Million 148Salix Pharma Completes Acquisition Of Santarus For US$2.6 Billion In Tender Offer 149Valeant Pharma Completes Acquisition Of Bausch & Lomb For US$ 8.7 Billion 151OlainFarm Acquires Additional 23.37% Stake In Silvanols, Pharma Products Manufacturer 153Valeant Pharma International Completes Acquisition Of Obagi Medical Products For US$418 Million 154Jelfa Pharm Sells Sanitas Pharma, Provider Of Marketing, Pharmacovigilance And Registration Services 156Valeant Pharma Completes Acquisition Of Natur Produkt International For Up To US$185 Million 157Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 158Valeant Pharma Completes Acquisition Of Medicis Pharma For US$2.6 Billion 160Jelfa Acquires Emo-Farm From ICN Polfa Rzeszow For US$10 Million 162Valeant Pharma To Acquire Silvanols, Pharmaceutical Manufacturer 163Valeant Pharma Completes Acquisition Of Orapharma From Water Street Healthcare Partners For US$442 Million 164Bausch & Lomb Completes Acquisition Of ISTA Pharma For US$500 Million 166Valeant 7

8 Pharma Acquires Pedinol Pharmacal, Provider Of Podiatric Medicine 168Valeant Pharma International Completes Acquisition Of Eyetech For Up To US$26 Million 169Valeant Pharma International Acquires 19.9% Stake In PeleNova Biotecnologia For US$10 Million 170Valeant Pharma Acquires Sports Nutrition Products Company, Probiotica Laboratorios, For US$86 Million 171Valeant Pharmaceuticals International Inc - Key Competitors 172Valeant Pharmaceuticals International Inc - Key Employees 173Valeant Pharmaceuticals International Inc - Locations And Subsidiaries 174Head Office 174Other Locations & Subsidiaries 174Recent Developments 182Financial Announcements 182May 08, 2018: Valeant Announces First-Quarter 2018 Results And Raises Revenue And Adjusted EBITDA (non-gaap) Guidance 182Feb 28, 2018: Valeant Announces Fourth- Quarter And Full-Year 2017 Financial Results 185Nov 07, 2017: Valeant Announces Third-Quarter 2017 Results 189Aug 08, 2017: Valeant Announces Second-Quarter 2017 Results 191May 09, 2017: Valeant Announces First Quarter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range 194Feb 28, 2017: Valeant Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Guidance 195Corporate Communications 199Sep 15, 2017: Valeant Commits $200,000 to Support Hurricane Relief Efforts 199Jun 19, 2017: John Paulson Joins Valeant Board Of Directors 200Jan 04, 2017: Valeant Pharmaceuticals Announces Addition Of Richard U. DeSchutter To Its Board Of Directors 201Legal and Regulatory 202May 15, 2018: Kyros Law Announces that it is Filing Legal Claims on Behalf of Valeant Pharmaceuticals Intl (NYSE: VRX) Investors 202Apr 12, 2018: Cosmo Pharmaceuticals announces unfavourable award of Arbitral Tribunal in respect of request to terminate Uceris License Agreement with Valeant 203Other Significant Developments 204May 08, 2018: Valeant Will Become Bausch Health Companies 204Feb 27, 2017: Valeant Announces Deployment Of Expanded Salix Sales Force To Capture Untapped Market Opportunity 205Appendix 206Methodology 206About GlobalData 206Contact Us 206Disclaimer 206 8

9 List Of Tables in Valeant Pharmaceuticals International Inc (VRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Updated: ] List of Tables Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Key Facts, Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD Valeant Pharmaceuticals International Inc, Deals By Therapy Area, 2012 to YTD Valeant Pharmaceuticals International Inc, Medical Devices Deals, 2012 to YTD Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD Valeant Canada Acquires Canadian Rights from Sanofi-aventis for Altace and Altace HCT 24 Valeant Pharma Acquires Certain Assets of Dendreon for USD495 Million 25 Valeant Pharma Acquires Non-Strategic Products from Marathon Pharma 27 PharmaSwiss Acquires Trademarks and Intellectual Property of Certain Products from Bristol-Myers Squibb for USD61 Million 28 Valeant Canada Acquires Dermatology Products from Valeo Pharma for USD23 Million 29 Valeant Pharma Acquires Pharma Brands from Probiotec 30 Salix Pharma Acquires Worldwide IP Rights To Amorphous Rifaximin From Olon 32 Valeant Pharma Acquires Medical Devices And Food Supplements Assets Of Croma-Pharma 33 Valeant Pharma Acquires US Rights To Targretin From Eisai 34 Valeant Pharma Acquires Visudyne Business From QLT For Up To USD132.5 Million 35 Valeant Pharma Completes Acquisition Of Certain Assets From Swiss Herbal Remedies For US$21 Million 36 Valeant Pharma Completes Acquisition Of AcneFree And Certain Assets From University Medical For Up To US$105 Million 37 Valeant Pharma Completes Acquisition Of Certain Assets From Atlantis Pharma For Up To US$74 Million 38 PreCision Dermatology Acquires Dermatology Products From Triax Pharma 39 Valeant Pharma Completes Acquisition Of Branded Generic Products Portfolio From Gerot Lannach For Up To US$184 Million 40 Precision Dermatology Raises Additional US$26 Million In Venture Financing 41 Pacific Equity and Carlyle Acquires inova Pharma from Valeant Pharma for USD930 Million 42 9

10 Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 44 Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 45 Namtall Enters into Licensing Agreement with Valeant Pharma 47 Salix Pharma Enters Into Licensing Agreement With Alfa Wassermann For Rifaximin 48 US WorldMeds and Salix Pharma Enter into Co-Promotion Agreement 49 Egalet Enters into Co-Promotion Agreement with OraPharma for SPRIX Nasal Spray 50 Obagi Medical Products Enters into Distribution Agreement with Nextcell Medical 51 Orexigen Therapeutics Enters into Distribution Agreement with Valeant Pharma 52 Orexigen Therapeutics Enters Into Distribution Agreement With Valeant For Contrave 53 Orexigen Therapeutics Enters into Distribution Agreement with Valeant Pharma for Mysimba 54 Swedish Orphan Biovitrum Enters into Distribution Agreement with PharmaSwiss 55 Lupin Enters into Distribution Agreement with Salix Pharma 56 Synergetics USA Enters Into Agreement With Cleveland Clinic To Develop Next Generation Intraoperative Devices 57 Kadmon Pharma Enters Into Co-Promotion Agreement With Valeant Pharma For Syprine Capsules 58 Valeant Pharmaceuticals International Partners With Living Proof 59 Pharmaxis Enters Into Distribution Agreement With PharmaSwiss For Bronchitol 60 Valeant Pharma Enters Into Co-Promotion Agreement With Actavis For Cordran Tape 61 Actavis Enters Into Co-Promotion Agreement With Valeant Pharma For Zovirax Cream 62 Actavis Enters Into Co-Marketing Agreement With Valeant Pharma For Zovirax Ointment 63 Swedish Orphan Biovitrum Enters Into Distribution Agreement With Pharmaswiss 64 Valeant Pharma Enters into Option Agreement with Bristol-Myers Squibb 65 Gentium Enters Into Distribution Agreement With PharmaSwiss For Defibrotide 66 Eisai Europe Enters Into Distribution Agreement With PharmaSwiss For Halaven 67 Bausch & Lomb Japan Enters Into Co-Marketing Agreement With Wakamoto Pharma 68 Valeant Pharma Enters into Licensing Agreement with Kaken Pharma for KP Glycyx Pharma to Enter into Licensing Agreement with Valeant Pharma 70 Swedish Orphan Biovitrum Enters into Licensing Agreement with Valeant Pharma 71 Valeant Pharma Amends Licensing Agreement with AstraZeneca 72 Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 73 InSite Vision Enters into Licensing Agreement with Nicox for AzaSite, AzaSite Xtr and BromSite 74 10

11 Cipla Amends Licensing Agreement with Salix Pharma for Rifaximin 75 Nicox Exercises Option Agreement with Bausch & Lomb to Co-Promote Latanoprostene Bunod 76 Sirona Biochem Expands Licensing Agreement with Valeant Pharma 77 Salix Pharma Enters Into Licensing Agreement With RedHill Biopharma For RHB-106 Encapsulated Bowel Preparation Product 78 Sirona Biochem Enters Into Licensing Agreement With Obagi Medical For TFC Valeant Pharma Enters into Licensing Agreement with SMG Pharma 80 Medicis Pharma Enters Into Licensing Agreement With Specialty Pharma Company 81 Medicis Pharma Enters Into Licensing Agreement With 3M For Immune Response Modifiers 82 Valeant Pharma Enters into Licensing Agreement with Norgine 83 Valeant Canada Enters into Licensing Agreement with Takeda Pharma for Edarbi and Edarbyclor 84 Bausch & Lomb Enters Into Licensing Agreement With Paragon BioTeck For Phenylephrine 85 Bausch & Lomb Enters Into Licensing Agreement With Eye Therapies For Technology To Treat Ocular Redness 86 Valeant Pharma Plans to Raise Funds through Public Offering of Securities 87 Atlantic Healthcare Raises USD24 million in Private Placement of Shares 88 Valeant Pharma Raises USD1162 Million in Public Offering of Common Stock 89 Valeant Pharma Completes Public Offering Of Shares For US$2.3 Billion 91 Bausch & Lomb Withdraws IPO 93 Valeant Pharma Raises USD586.5 Private Placement of 8.5% Notes Due Valeant Pharma Raises USD1.17 Billion in Private Placement of 9.25% Senior Notes Due Valeant Pharma Raises USD1.18 Billion in Private Placement of 9% Notes Due Valeant Pharma Raises USD591.4 Million in Private Placement of 5.5% Notes Due Valeant Pharma Raises USD801.4 Million in Private Placement of Notes 99 Valeant Pharma Raises USD1.5 Billion in Public Offering of 7% Notes Due Valeant Pharma Raises USD1 Billion in Public Offering of 6.5% Notes Due Valeant Pharma Raises USD3.25 Billion in Private Placement of 5.875% Notes Due Valeant Pharma Raises USD1.58 Billion in Private Placement of 4.5% Notes Due Valeant Pharma Raises USD2 Billion in Private Placement of 5.375% Notes Due Valeant Pharma Raises USD3.25 Billion in Private Placement of 6.125% Notes Due Valeant Pharma Raises USD1 Billion in Private Placement of 5.5% Senior Notes Due Valeant Pharma to Raises USD8.8 Billion in Public Offering of Bonds

12 Valeant Pharma to Raises USD2.5 Billion in Public Offering of Notes 108 Valeant Pharma Completes Private Placement Of Notes Due 2021 For US$900 Million 109 Valeant Pharma Completes Private Placement Of Notes Due 2021 For US$1.62 Billion 110 Valeant Pharma Completes Private Placement Of Notes Due 2018 For US$1.6 Billion 111 Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$1.75 Billion 112 Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$500 Million 113 Medicis Pharma Completes Public Offering Of Convertible Senior Notes Due 2017 For US$500 Million 114 Salix Pharma Completes Private Placement Of 1.5% Convertible Senior Notes Due 2019 For US$690 Million 116 Pharming Acquires Rights to Ruconest from Valeant Pharma for USD125 Million 117 Valeant Pharma Receives Unsolicited Bids for its Core Assets 119 Valeant Pharma May Sell its Dermatology and Cancer Drugs 120 Valeant Pharma Plans to Sell Neuro Business 121 IGI Labs Acquires Two Ophthalmic Drug Products from Valeant Pharma for USD1.5 Million 122 Galderma Completes Acquisition of Aesthetic Dermatology Assets from Valeant Pharma for USD1.4 Billion 123 Piramal Enterprises Acquires Caladryl Brand From Valeant Pharma 124 Hyperion Therapeutics Completes Acquisition Of Rights To Buphenyl And Ammonul From Ucyclyd Pharma For US$51 Million 125 Actavis Acquires Worldwide Rights To Metronidazole 1.3% Vaginal Gel From Valeant Pharma For US$55 Million 127 PreCision Dermatology Acquires Dermatology Products From Triax Pharma 128 Hyperion Therapeutics Acquires Rights Of Ravicti From Ucyclyd Pharma 129 Mylan Acquires Clindamycin Phosphate And Benzoyl Peroxide Gel From Valeant Pharma International 130 Valeant Pharma Sells Sprout Pharma 131 Haitong International Zhonghua Finance Acquires Obagi Medical Products from Valeant Pharma for USD190 Million 132 Sanpower Acquires Dendreon Pharma from Valeant Pharma for USD820 Million 133 Pershing Square Capital Management Sells its Investment in Valeant Pharma 134 Takeda Pharma May Acquire Salix Pharma for up to USD10 Billion 135 Valeant Pharma May Sell Amoun Pharma 136 Valeant Pharma to Acquire Mercury (Cayman) 137 Valeant Pharma Acquires Sprout Pharma 139 Valeant Pharma Acquires Salix Pharma for USD10.9 Billion

13 Valeant Pharma Acquires Nicox for USD20 Million 144 Valeant Canada Acquires CROMA Pharma Canada 145 Valeant Pharma Completes Acquisition of PreCision Dermatology 146 Valeant Pharma Acquires ECR Pharma from Akorn for USD41 Million 148 Salix Pharma Completes Acquisition Of Santarus For US$2.6 Billion In Tender Offer 149 Valeant Pharma Completes Acquisition Of Bausch & Lomb For US$ 8.7 Billion 151 OlainFarm Acquires Additional 23.37% Stake In Silvanols, Pharma Products Manufacturer 153 Valeant Pharma International Completes Acquisition Of Obagi Medical Products For US$418 Million 154 Jelfa Pharm Sells Sanitas Pharma, Provider Of Marketing, Pharmacovigilance And Registration Services 156 Valeant Pharma Completes Acquisition Of Natur Produkt International For Up To US$185 Million 157 Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 158 Valeant Pharma Completes Acquisition Of Medicis Pharma For US$2.6 Billion 160 Jelfa Acquires Emo-Farm From ICN Polfa Rzeszow For US$10 Million 162 Valeant Pharma To Acquire Silvanols, Pharmaceutical Manufacturer 163 Valeant Pharma Completes Acquisition Of Orapharma From Water Street Healthcare Partners For US$442 Million 164 Bausch & Lomb Completes Acquisition Of ISTA Pharma For US$500 Million 166 Valeant Pharma Acquires Pedinol Pharmacal, Provider Of Podiatric Medicine 168 Valeant Pharma International Completes Acquisition Of Eyetech For Up To US$26 Million 169 Valeant Pharma International Acquires 19.9% Stake In PeleNova Biotecnologia For US$10 Million 170 Valeant Pharma Acquires Sports Nutrition Products Company, Probiotica Laboratorios, For US$86 Million 171 Valeant Pharmaceuticals International Inc, Key Competitors 172 Valeant Pharmaceuticals International Inc, Key Employees 173 Valeant Pharmaceuticals International Inc, Other Locations 174 Valeant Pharmaceuticals International Inc, Subsidiaries

14 List Of Figures, Charts and Diagrams in Valeant Pharmaceuticals International Inc (VRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Updated: ] List of Figures Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD Valeant Pharmaceuticals International Inc, Medical Devices Deals, 2012 to YTD

15 How to Buy... Valeant Pharmaceuticals International Inc (VRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Updated: ] Option 1 - Online Go to our website and pay online with any major debit or credit card: Option 2 - Request a Proforma Invoice Fill in the details below, and either Scan this page and it to us at office@sectorpublishing.com or Fax it to us at +44 (0) We will send you a Proforma Invoice and deliver your report on settlement. Your Name: Job Title: Your Your Contact Phone: Company Name: Address: Post/Zip Code: Country: P.O. Number: Any Other Instructions: Pricing Options: (please tick one) $250 Single User Price $500 Site License Price $750 Enterprise License Price Payment Options: (please tick one) Online Credit Card (we will you the invoice with a payment link) Direct Wire Transfer (we will you the invoice with our bank details) Authorising Signature: Option 3 - Phone Us on +44 (0) We will be delighted to give you our personal attention. 15